Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables - Other (2020 - 2025)

Historic Receivables - Other for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $1.8 million.

  • Caribou Biosciences' Receivables - Other rose 861.56% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 861.56%. This contributed to the annual value of $1.8 million for FY2024, which is 2003.5% down from last year.
  • As of Q3 2025, Caribou Biosciences' Receivables - Other stood at $1.8 million, which was up 861.56% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Receivables - Other ranged from a high of $7.6 million in Q2 2021 and a low of $1.5 million during Q2 2023
  • Its 5-year average for Receivables - Other is $2.8 million, with a median of $2.1 million in 2022.
  • As far as peak fluctuations go, Caribou Biosciences' Receivables - Other skyrocketed by 4891.36% in 2021, and later tumbled by 5994.24% in 2023.
  • Caribou Biosciences' Receivables - Other (Quarter) stood at $5.5 million in 2021, then plummeted by 59.02% to $2.2 million in 2022, then rose by 1.74% to $2.3 million in 2023, then fell by 20.03% to $1.8 million in 2024, then changed by 0.0% to $1.8 million in 2025.
  • Its Receivables - Other was $1.8 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.8 million in Q1 2025.